Dottikon Es Holding AG
SIX:DESN

Watchlist Manager
Dottikon Es Holding AG Logo
Dottikon Es Holding AG
SIX:DESN
Watchlist
Price: 216.5 CHF Market Closed
Market Cap: 3B CHF
Have any thoughts about
Dottikon Es Holding AG?
Write Note

Net Margin
Dottikon Es Holding AG

22.8%
Current
25%
Average
4.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
22.8%
=
Net Income
75.5m
/
Revenue
330.7m

Net Margin Across Competitors

Country CH
Market Cap 3B CHF
Net Margin
23%
Country US
Market Cap 87.2B USD
Net Margin
11%
Country US
Market Cap 68.1B USD
Net Margin
13%
Country JP
Market Cap 10.2T JPY
Net Margin
21%
Country CH
Market Cap 36.4B CHF
Net Margin
15%
Country CN
Market Cap 235.1B CNY
Net Margin
8%
Country US
Market Cap 32.3B USD
Net Margin
7%
Country US
Market Cap 28.1B USD
Net Margin
8%
Country CH
Market Cap 25.9B EUR
Net Margin
20%
Country IN
Market Cap 2.2T INR
Net Margin
13%
Country DK
Market Cap 165.6B DKK
Net Margin
17%
No Stocks Found

Dottikon Es Holding AG
Glance View

Market Cap
3B CHF
Industry
Chemicals

Dottikon Es Holding AG stands as one of Switzerland's understated gems in the realm of fine chemicals and pharmaceuticals. Born from Switzerland's rich tradition of precision and quality, the company operates primarily in the realm of exclusive synthesis, tailored to meet the stringent demands of the pharmaceuticals industry. At its core, Dottikon specializes in hazardous chemical reactions, priding itself on an ability to transform complex chemical processes into high-quality results. This specialization provides a competitive edge, allowing Dottikon to focus on developing innovative and complex molecules which serve as active pharmaceutical ingredients (APIs). It's a business model that not only underscores the company's technical expertise but also its commitment to safety and environmental stewardship, given the heightened risks associated with hazardous materials. Revenue for Dottikon is chiefly generated from strategic partnerships with major pharmaceutical companies. By offering a unique combination of research and development capabilities coupled with state-of-the-art production facilities, Dottikon caters to bespoke needs, from initial developmental scales to full-fledged commercial production runs. The trust and collaboration between Dottikon and its clients are pivotal, as the company becomes an indispensable partner in the clients’ supply chain. As the pharmaceutical sector continues to evolve and demand for specialized molecules increases, Dottikon’s focus on exclusivity and expertise positions it well within the industry, ensuring steady demand and solidifying its role as a reliable, albeit lesser-known, catalyst in advancing pharmaceutical innovations.

DESN Intrinsic Value
163.42 CHF
Overvaluation 25%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
22.8%
=
Net Income
75.5m
/
Revenue
330.7m
What is the Net Margin of Dottikon Es Holding AG?

Based on Dottikon Es Holding AG's most recent financial statements, the company has Net Margin of 22.8%.